Journal
JOURNAL OF CLINICAL RESEARCH IN PEDIATRIC ENDOCRINOLOGY
Volume 9, Issue 3, Pages 208-215Publisher
GALENOS YAYINCILIK
DOI: 10.4274/jcrpe.4125
Keywords
Growth; insulin-like growth factor-I; growth hormone deficiency; growth hormone therapy; clinical decision making
Categories
Funding
- NIDDK NIH HHS [T32 DK063688] Funding Source: Medline
Ask authors/readers for more resources
Objective: To describe the range of insulin-like growth factor-I (IGF-I) z-score values (IGF-Iz) and growth hormone (GH) dose adjustments in pre-pubertal patients with GH deficiency (GHD) treated with GH in a single tertiary care center. Methods: This is a retrospective review of GH-treated patients of ages = 9 years with GHD, seen in an endocrinology clinic in 2013-2014. Patient demographics and pre-treatment anthropometrics, GH treatment duration, IGF-Iz, and GH dosage (mg/kg/week) were extracted. Multipredictor linear regression was used to evaluate the associations between IGF-Iz and GH dosage and subject gender, race, insurance type, age, and clinical characteristics. Logistic regression was used to calculate the odds ratio of direction of GH dose adjustment (decrease/no change versus increase) and IGF-Iz category based on patient clinical characteristics, accounting for provider random effect. Results: Forty-one percent (57/139) of IGF-Iz were outside the normal range of between -2 and +2 standard deviation; the majority of IGF-Iz beyond the normal range (93%) were supraphysiologic [> + 2 standard deviation score (SDS)]. Of the IGF-Iz > + 2, 10/53 (18%) were followed by a GH dose increase and 30/53 (57%) had no dose change. Patient clinical characteristics and demographics did not significantly increase the odds of being in the IGF-Iz > + 2 SDS category or having a dose increase in multipredictor logistic regression models. Conclusion: GH dosages and IGF-Iz varied, without significant patient clinical predictors. IGF-Iz was frequently supraphysiologic, and these levels often did not prompt a reduction in GH dose, likely influenced by a variety of factors. Our study emphasizes the need for better understanding of long-term safety and efficacy of maintaining supraphysiologic levels of IGF-Iz.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available